Affymetrix Announces Expansion of QuantiGene® ViewRNA License for in vitro Diagnostics and Becomes Exclusive Licensee for Chromogenic Applications
Affymetrix, Inc. (NASDAQ: AFFX) today announced the expansion of its license agreement with Siemens Healthcare Diagnostics for the company's branched DNA (bDNA) technology whereby Affymetrix is the exclusive licensee for in situ products, including in vitro diagnostics. This expanded license grants Affymetrix rights to develop and sell in situ QuantiGene® ViewRNA products, currently for research use only, in the in vitro diagnostic market. Additionally, this license includes exclusive rights to alkaline phosphatase conjugated oligonucleotides and their use in bDNA methods for in situ detection utilizing Fast Red substrates.
In light of this expanded license, along with existing technology and other recently announced collaborations, such as the research collaboration with Massachusetts General Hospital, the automation collaboration with Leica Microsystems, and the worldwide distribution of ScreenCell's circulating tumor cell technology, Affymetrix plans to commercialize a platform of total solutions involving an assay menu of chromogenic-based applications of the bDNA technology which provide highly sensitive, multiplex analyses in both brightfield (CISH) and fluorescence (FISH) microscopy and options for automation.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.